Clinical Evaluation of Tumor Imaging with<sup>201</sup>TI Chloride

Hisada, Kinichi; Tonami, Norihisa; Miyamae, Tatsuya; Hiraki, Yoshio; Yamazaki, Toshio; Maeda, Takeyasu; Nakajo, Masayuki

doi:10.1148/129.2.497

Cited by 90 publications

(23 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The number of radiopharmaceuticals, such as 2°~T1, proposed for tumour imaging is in the hundreds, and some have achieved widespread acceptance in clinical imaging [14][15][16][17]. 2°~T1 has been shown to be an effective radiopharmaceutical in the detection of many types of malignancy [16][17][18][19].…”

Section: Discussionmentioning

confidence: 99%

“…2°~T1 has been shown to be an effective radiopharmaceutical in the detection of many types of malignancy [16][17][18][19]. In a series of malignancies evaluated by Hisada et al, two patients were shown to have primary carcinomas of the breast by means of 2°~T1 imaging [16]. Hassan et al demonstrated that 2°~T1 accumulated in 20 of 20 patients with primary carcinomas of the breast [8].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

The use of technetium-99m methoxyisobutylisonitrile breast scintigraphy to evaluate palpable breast masses

1994

View full text Add to dashboard Cite

Thirty-eight female patients (age range: 31-79 years) with breast masses underwent technetium-99m methoxyisobutylisonitrile (99mTc-MIBI) breast scintigraphy in order to assess the value of this technique in the detection of breast carcinomas and in their differentiation from benign breast masses. The results showed that 27 of the 32 cases of breast carcinoma were detected by 99mTc-MIBI breast scintigraphy. In contrast, none of the six benign lesions could be detected by this method. The diagnostic sensitivity, specificity and accuracy were 84%, 100% and 87%, respectively, in the differentiation of malignant and benign breast masses. In conclusion, we consider 99mTc-MIBI breast scintigraphy is useful in distinguishing malignancies from benign breast masses.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

The use of technetium-99m methoxyisobutylisonitrile breast scintigraphy to evaluate palpable breast masses

1994

View full text Add to dashboard Cite

show abstract

“…The number of radiopharmaceuticals proposed for tumour imaging is in the hundreds, but only two simple cations, gallium-67 and thallium-201, have achieved widespread acceptance in clinical imaging [4,[7][8][9]. However, poor emission characteristics, problems in respect of delayed imaging time and cyclotron production, and lack of specificity are significant disadvantages of these agents.…”

Section: Discussionmentioning

confidence: 99%

Differentiation of single solid lesions in the lungs by means of single-photon emission tomography with technetium-99m methoxyisobutylisonitrile

et al. 1993

View full text Add to dashboard Cite

The value of technetium-99m methoxyisobutylisonitrile (MIBI) single-photon emission tomography (SPET) of the chest in differentiating lung carcinomas of various histological types and benign lesions was assessed in 54 patients (47 males and 7 females aged 19-77 years) with single solid lung masses. Chest radiography had indicated that 46 of the lesions were malignant (8 small cell carcinomas, 14 epidermoid carcinomas, 18 adenocarcinomas and 6 undifferentiated large cell carcinomas) and eight, benign. Ten, volunteers who also agreed to undergo 99mTc-MIBI SPET of the chest served as a control group. The results showed that only 65% (30/46) of the lung malignancies were detected by 99mTc-MIBI SPECT, including 63% (5/8) of the small cell carcinomas, 64% (9/14) of the epidermoid carcinomas, 72% (13/18) of the adenocarcinomas and 50% (3/6) of the undifferentiated large cell carcinomas. However, 75% (6/8) of the benign lesions were also detected. The diagnostic sensitivity, specificity and accuracy in differentiating malignant and benign lesions were 65%, 57% and 70%, respectively. We conclude that 99mTc-MIBI is of limited use in the differentiation of single solid lesions in the lungs.

show abstract

“…Thallium-201 has been used to evaluate tumour viability [15][16][17][18][19][20], because, like potassium, 2°aT1 passes intracellularly to viable tumour and shows rapid clearance from blood [21]. Particularly for the evaluation of the viability of intracerebral lesions, use of 2°1T1 has been advocated because of its low uptake by normal brain [7,22,23].…”

Section: Discussionmentioning

confidence: 99%

Time sequential single photon emission computed tomography studies in brain tumour using thallium-201

et al. 1993

View full text Add to dashboard Cite

Time sequential single photon emission computed tomography (SPECT) studies using thallium-201 were performed in 25 patients with brain tumours to evaluate the kinetics of thallium in the tumour and the biological malignancy grade preoperatively. After acquisition and reconstruction of SPECT data from 1 min post injection to 48 h (1, 2, 3, 4, 5, 6, 7, 8, 9, 10 and 15-20 min, followed by 4-6, 24 and 48 h), the thallium uptake ratio in the tumour versus the homologous contralateral area of the brain was calculated and compared with findings of X-ray CT, magnetic resonance imaging, cerebral angiography and histological investigations. Early uptake of thallium in tumours was related to tumour vascularity and the disruption of the blood-brain barrier. High and rapid uptake and slow reduction of thallium indicated a hypervascular malignant tumour; however, high and rapid uptake but rapid reduction of thallium indicated a hypervascular benign tumour, such as meningioma. Hypovascular and benign tumours tended to show low uptake and slow reduction of thallium. Long-lasting retention or uptake of thallium indicates tumour malignancy.

show abstract

Clinical Evaluation of Tumor Imaging with²⁰¹TI Chloride

Cited by 90 publications

References 4 publications

The use of technetium-99m methoxyisobutylisonitrile breast scintigraphy to evaluate palpable breast masses

The use of technetium-99m methoxyisobutylisonitrile breast scintigraphy to evaluate palpable breast masses

Differentiation of single solid lesions in the lungs by means of single-photon emission tomography with technetium-99m methoxyisobutylisonitrile

Time sequential single photon emission computed tomography studies in brain tumour using thallium-201

Contact Info

Product

Resources

About

Clinical Evaluation of Tumor Imaging with201TI Chloride

Cited by 90 publications

References 4 publications

The use of technetium-99m methoxyisobutylisonitrile breast scintigraphy to evaluate palpable breast masses

The use of technetium-99m methoxyisobutylisonitrile breast scintigraphy to evaluate palpable breast masses

Differentiation of single solid lesions in the lungs by means of single-photon emission tomography with technetium-99m methoxyisobutylisonitrile

Time sequential single photon emission computed tomography studies in brain tumour using thallium-201

Contact Info

Product

Resources

About

Clinical Evaluation of Tumor Imaging with²⁰¹TI Chloride